Normal growth and essential fatty acid status in children with intestinal failure on lipid limitation

Gillian Lam, Irina G. Strogach, Nicole Baron, John F. Thompson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: Lipid limitation, that is, ≤1 g-kg-1-day-1 of soy oil lipid emulsion (SOLE), has been suggested as a method to reduce the risk of intestinal failure (IF)-associated liver disease (IFALD). There are limited data as to the effects of this strategy on growth and essential fatty acid (EFA) status. The aim of the study was to assess growth, prevalence of cholestasis, and EFA deficiency in patients with IF who were provided daily SOLE at a dose ≤1 g-kg-1-day-1. Methods: Medical records were retrospectively reviewed from 9 patients age 16 months to 8 years who had IF requiring parenteral nutrition support for >12 months. Parenteral nutrition supplied a mean of 53% of total energy (range 24%-86%). Results: Mean SOLE dose was 0.61 g-kg-1-day-1 (range 0.4-0.81 g-kg-1-day-1). After 1 month of lipid limitation between 2011 and 2014, no patient developed IFALD as defined by a direct bilirubin >2 mg/dL. The median direct bilirubin was 0.1 mg/dL (range 0.075-0.85 mg/dL). No patient developed EFA deficiency as defined by a triene-to-tetraene ratio >0.2 (median 0.026, range 0.017-0.076). Height z scores increased from mean of-2.568 (range-10.8 to 0.878) to-0.484 (range-3.546 to 0.822). Weight z scores increased from mean of-1.412 (range-5.871 to 0.906) to-0.595 (range-2.178 to 0.926). Conclusions: In this case series, lipid limitation allowed normal growth while preventing the development of cholestasis and EFA deficiency.

Original languageEnglish (US)
Pages (from-to)335-340
Number of pages6
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume62
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Essential Fatty Acids
Lipids
Growth
Emulsions
Oils
Cholestasis
Parenteral Nutrition
Bilirubin
Liver Diseases
Medical Records
Weights and Measures

Keywords

  • Intestinal failure
  • intestinal failure-associated liver disease
  • intravenous lipids
  • lipid emulsion
  • lipid limitation
  • parenteral nutrition- associated liver disease
  • short bowel syndrome

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

Normal growth and essential fatty acid status in children with intestinal failure on lipid limitation. / Lam, Gillian; Strogach, Irina G.; Baron, Nicole; Thompson, John F.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 62, No. 2, 01.02.2016, p. 335-340.

Research output: Contribution to journalArticle

@article{9e06adf5ca314a539a1f47145ca027c5,
title = "Normal growth and essential fatty acid status in children with intestinal failure on lipid limitation",
abstract = "Objectives: Lipid limitation, that is, ≤1 g-kg-1-day-1 of soy oil lipid emulsion (SOLE), has been suggested as a method to reduce the risk of intestinal failure (IF)-associated liver disease (IFALD). There are limited data as to the effects of this strategy on growth and essential fatty acid (EFA) status. The aim of the study was to assess growth, prevalence of cholestasis, and EFA deficiency in patients with IF who were provided daily SOLE at a dose ≤1 g-kg-1-day-1. Methods: Medical records were retrospectively reviewed from 9 patients age 16 months to 8 years who had IF requiring parenteral nutrition support for >12 months. Parenteral nutrition supplied a mean of 53{\%} of total energy (range 24{\%}-86{\%}). Results: Mean SOLE dose was 0.61 g-kg-1-day-1 (range 0.4-0.81 g-kg-1-day-1). After 1 month of lipid limitation between 2011 and 2014, no patient developed IFALD as defined by a direct bilirubin >2 mg/dL. The median direct bilirubin was 0.1 mg/dL (range 0.075-0.85 mg/dL). No patient developed EFA deficiency as defined by a triene-to-tetraene ratio >0.2 (median 0.026, range 0.017-0.076). Height z scores increased from mean of-2.568 (range-10.8 to 0.878) to-0.484 (range-3.546 to 0.822). Weight z scores increased from mean of-1.412 (range-5.871 to 0.906) to-0.595 (range-2.178 to 0.926). Conclusions: In this case series, lipid limitation allowed normal growth while preventing the development of cholestasis and EFA deficiency.",
keywords = "Intestinal failure, intestinal failure-associated liver disease, intravenous lipids, lipid emulsion, lipid limitation, parenteral nutrition- associated liver disease, short bowel syndrome",
author = "Gillian Lam and Strogach, {Irina G.} and Nicole Baron and Thompson, {John F.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1097/MPG.0000000000000948",
language = "English (US)",
volume = "62",
pages = "335--340",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Normal growth and essential fatty acid status in children with intestinal failure on lipid limitation

AU - Lam, Gillian

AU - Strogach, Irina G.

AU - Baron, Nicole

AU - Thompson, John F.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objectives: Lipid limitation, that is, ≤1 g-kg-1-day-1 of soy oil lipid emulsion (SOLE), has been suggested as a method to reduce the risk of intestinal failure (IF)-associated liver disease (IFALD). There are limited data as to the effects of this strategy on growth and essential fatty acid (EFA) status. The aim of the study was to assess growth, prevalence of cholestasis, and EFA deficiency in patients with IF who were provided daily SOLE at a dose ≤1 g-kg-1-day-1. Methods: Medical records were retrospectively reviewed from 9 patients age 16 months to 8 years who had IF requiring parenteral nutrition support for >12 months. Parenteral nutrition supplied a mean of 53% of total energy (range 24%-86%). Results: Mean SOLE dose was 0.61 g-kg-1-day-1 (range 0.4-0.81 g-kg-1-day-1). After 1 month of lipid limitation between 2011 and 2014, no patient developed IFALD as defined by a direct bilirubin >2 mg/dL. The median direct bilirubin was 0.1 mg/dL (range 0.075-0.85 mg/dL). No patient developed EFA deficiency as defined by a triene-to-tetraene ratio >0.2 (median 0.026, range 0.017-0.076). Height z scores increased from mean of-2.568 (range-10.8 to 0.878) to-0.484 (range-3.546 to 0.822). Weight z scores increased from mean of-1.412 (range-5.871 to 0.906) to-0.595 (range-2.178 to 0.926). Conclusions: In this case series, lipid limitation allowed normal growth while preventing the development of cholestasis and EFA deficiency.

AB - Objectives: Lipid limitation, that is, ≤1 g-kg-1-day-1 of soy oil lipid emulsion (SOLE), has been suggested as a method to reduce the risk of intestinal failure (IF)-associated liver disease (IFALD). There are limited data as to the effects of this strategy on growth and essential fatty acid (EFA) status. The aim of the study was to assess growth, prevalence of cholestasis, and EFA deficiency in patients with IF who were provided daily SOLE at a dose ≤1 g-kg-1-day-1. Methods: Medical records were retrospectively reviewed from 9 patients age 16 months to 8 years who had IF requiring parenteral nutrition support for >12 months. Parenteral nutrition supplied a mean of 53% of total energy (range 24%-86%). Results: Mean SOLE dose was 0.61 g-kg-1-day-1 (range 0.4-0.81 g-kg-1-day-1). After 1 month of lipid limitation between 2011 and 2014, no patient developed IFALD as defined by a direct bilirubin >2 mg/dL. The median direct bilirubin was 0.1 mg/dL (range 0.075-0.85 mg/dL). No patient developed EFA deficiency as defined by a triene-to-tetraene ratio >0.2 (median 0.026, range 0.017-0.076). Height z scores increased from mean of-2.568 (range-10.8 to 0.878) to-0.484 (range-3.546 to 0.822). Weight z scores increased from mean of-1.412 (range-5.871 to 0.906) to-0.595 (range-2.178 to 0.926). Conclusions: In this case series, lipid limitation allowed normal growth while preventing the development of cholestasis and EFA deficiency.

KW - Intestinal failure

KW - intestinal failure-associated liver disease

KW - intravenous lipids

KW - lipid emulsion

KW - lipid limitation

KW - parenteral nutrition- associated liver disease

KW - short bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=84957083449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957083449&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000000948

DO - 10.1097/MPG.0000000000000948

M3 - Article

C2 - 26301616

AN - SCOPUS:84957083449

VL - 62

SP - 335

EP - 340

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 2

ER -